(Q38170161)

30 August 2017

title

Role of IL28B for chronic hepatitis C treatment toward personalized medicine (English)

1 reference

30 August 2017

main subject

personalized medicine

1 reference

1 reference

1 reference

1 reference

3

Yasuhito Tanaka

1 reference

30 August 2017

Kentaro Matsuura

1

1 reference

30 August 2017

Tsunamasa Watanabe

series ordinal

2

1 reference

30 August 2017

publication date

1 February 2014

1 reference

Journal of Gastroenterology and Hepatology

30 August 2017

published in

1 reference

30 August 2017

volume

29

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

241-249

1 reference

The global burden of hepatitis C

30 August 2017

cites work

1 reference

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

21 January 2018

1 reference

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C pharmacogenetics: state of the art in 2010.

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection

21 January 2018

1 reference

Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection

21 January 2018

1 reference

HLA-C and KIR genes in hepatitis C virus infection.

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users

21 January 2018

1 reference

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors

21 January 2018

1 reference

Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

21 January 2018

1 reference

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.

21 January 2018

1 reference

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection

21 January 2018

1 reference

IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5.

21 January 2018

1 reference

Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection

21 January 2018

1 reference

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

21 January 2018

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts

21 January 2018

1 reference

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

21 January 2018

1 reference

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

21 January 2018

1 reference

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

21 January 2018

1 reference

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

21 January 2018

1 reference

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

21 January 2018

1 reference

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

21 January 2018

1 reference

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

21 January 2018

1 reference

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

21 January 2018

1 reference

Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis

21 January 2018

1 reference

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Interferon signaling and treatment outcome in chronic hepatitis C

21 January 2018

1 reference

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response

21 January 2018

1 reference

Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response

21 January 2018

1 reference

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons

21 January 2018

1 reference

Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene

21 January 2018

1 reference

Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection

21 January 2018

1 reference

Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus

21 January 2018

1 reference

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction

21 January 2018

1 reference

IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.12475

1 reference

30 August 2017

1 reference